Abstract
For radiotherapy, biomolecules such as intact antibodies, antibody fragments, peptides, DNAs and other oligomers have all been labeled with radiorhenium (186Re and 188Re). Three different approaches have been employed that may be referred to as direct, indirect and integral labeling. Direct labeling applies to proteins and involves the initial reduction of endogenous disulfide bridges to provide chelation sites. Indirect labeling can apply to most biomolecules and involves the initial attachment of an exogenous chelator. Finally, integral labeling is a special case applying only to small molecules in which the metallic radionuclide serves to link two parts of a biomolecule together in forming the labeled complex. While the number of varieties for the direct and integral radiolabeling approaches is rather limited, a fairly large and diverse number of chelators have been reported in the case of indirect labeling. Our objective herein is to provide an overview of the various chelators that have been used in the indirect labeling of biomolecules with radiorhenium, including details on the labeling procedures, the stability of the radiolabel and, where possible, the influence of the label on biological properties.
Keywords: Radiolabeling, rhenium-188, rhenium-186, bifunctional chelator, radioimmunotherapy, biomolecule, coordination chemistry, radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry
Title: Labeling Biomolecules with Radiorhenium - A Review of the Bifunctional Chelators
Volume: 7 Issue: 3
Author(s): Guozheng Liu and Donald J. Hnatowich
Affiliation:
Keywords: Radiolabeling, rhenium-188, rhenium-186, bifunctional chelator, radioimmunotherapy, biomolecule, coordination chemistry, radiopharmaceuticals
Abstract: For radiotherapy, biomolecules such as intact antibodies, antibody fragments, peptides, DNAs and other oligomers have all been labeled with radiorhenium (186Re and 188Re). Three different approaches have been employed that may be referred to as direct, indirect and integral labeling. Direct labeling applies to proteins and involves the initial reduction of endogenous disulfide bridges to provide chelation sites. Indirect labeling can apply to most biomolecules and involves the initial attachment of an exogenous chelator. Finally, integral labeling is a special case applying only to small molecules in which the metallic radionuclide serves to link two parts of a biomolecule together in forming the labeled complex. While the number of varieties for the direct and integral radiolabeling approaches is rather limited, a fairly large and diverse number of chelators have been reported in the case of indirect labeling. Our objective herein is to provide an overview of the various chelators that have been used in the indirect labeling of biomolecules with radiorhenium, including details on the labeling procedures, the stability of the radiolabel and, where possible, the influence of the label on biological properties.
Export Options
About this article
Cite this article as:
Liu Guozheng and Hnatowich J. Donald, Labeling Biomolecules with Radiorhenium - A Review of the Bifunctional Chelators, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618144
DOI https://dx.doi.org/10.2174/187152007780618144 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Recent Patents on Anti-Cancer Drug Discovery PPAR Modulators and PPAR Pan Agonists for Metabolic Diseases: The Next Generation of Drugs Targeting Peroxisome Proliferator-Activated Receptors?
Current Topics in Medicinal Chemistry In Silico Elucidation of the Plausible Inhibitory Potential of Withaferin A of Withania Somnifera Medicinal Herb Against Breast Cancer Targeting Estrogen Receptor
Current Pharmaceutical Biotechnology Platinum-Intercalator Conjugates: From DNA-Targeted Cisplatin Derivatives to Adenine Binding Complexes as Potential Modulators of Gene Regulation
Current Topics in Medicinal Chemistry Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation
Current Drug Discovery Technologies Cinnamic Acid Derivatives Induce Cell Cycle Arrest in Carcinoma Cell Lines
Medicinal Chemistry Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds Radionuclide Based Imaging of Prostate Cancer
Current Topics in Medicinal Chemistry Therapeutics Based on microRNA: A New Approach for Liver Cancer
Current Genomics A Current Review on Drug Loaded Nanofibers: Interesting and Valuable Platform for Skin Cancer Treatment
Pharmaceutical Nanotechnology Development of Thiazole-5-carboxylate Derivatives as Selective Inhibitors of Monoacylglycerol Lipase as Target in Cancer
Mini-Reviews in Medicinal Chemistry Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Hepatitis C Virus NS3/4A Protease Inhibitors
Recent Patents on Anti-Infective Drug Discovery Dietary Management of Gestational Diabetes Mellitus
Current Nutrition & Food Science Role of Immunostimulatory Molecules in Poultry Vaccines
Recent Patents on Biotechnology Sustained Delivery of Tamoxifen from a Nanofluidic Delivery Platform
Drug Delivery Letters Current Progresses and Trends in the Development of Progesterone Receptor Modulators
Current Medicinal Chemistry Pharmacokinetics and Disposition of Nanomedicine Using Biodegradable PEG/PCL Polymers as Drug Carriers
Current Drug Metabolism Recent Progress in Chemically Modified siRNAs
Mini-Reviews in Medicinal Chemistry